Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) announced today that it will release its fourth-quarter and full-year 2024 financial results on Wednesday, Feb. 26, 2025, prior to the open of the U.S. financial markets.

Following the announcement, Madrigal’s management will host a live webcast at 8 a.m. Eastern Time to review the Company’s financial and operating results.

The live webcast may be accessed at the Investor Relations section of the Madrigal Pharmaceuticals website. To ensure a timely connection, it is recommended that participants register here at least 15 minutes prior to the scheduled webcast.

The webcast will be available approximately two hours after the live webcast.

About Madrigal PharmaceuticalsMadrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a liver disease with high unmet medical need. Madrigal’s medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-β agonist designed to target key underlying causes of MASH. For more information, visit www.madrigalpharma.com.

Investor ContactTina Ventura, IR@madrigalpharma.com

Media ContactChristopher Frates, media@madrigalpharma.com

Madrigal Pharmaceuticals (NASDAQ:MDGL)
Historical Stock Chart
From Jan 2025 to Feb 2025 Click Here for more Madrigal Pharmaceuticals Charts.
Madrigal Pharmaceuticals (NASDAQ:MDGL)
Historical Stock Chart
From Feb 2024 to Feb 2025 Click Here for more Madrigal Pharmaceuticals Charts.